Discovering and improving novel peptide therapeutics

Area of Science:

• Biotechnology
• Drug Discovery
• Pharmacology

Background:

• Peptides possess high target specificity and affinity, with a smaller size than antibodies.
• Therapeutic peptides face limitations due to protease susceptibility and short serum half-life, hindering drug development.
• Few recombinant library-derived peptides have successfully transitioned to marketed drugs.

Purpose of the Study:

• To review recent technological advancements addressing the limitations of therapeutic peptides.
• To highlight strategies for enhancing peptide protease resistance and extending serum half-life.
• To assess the potential of these technologies in establishing peptides as a mainstream drug class.

Main Methods:

• Development of selection methodologies to enhance protease resistance in peptides.
• Application of protein engineering techniques like pegylation and antibody Fc attachment.
• Utilizing serum albumin binding to prolong peptide circulation time.

Main Results:

• Emerging technologies demonstrate significant improvements in peptide stability and pharmacokinetic profiles.
• Combined approaches show promise in overcoming key hurdles for peptide drug development.
• These advancements are poised to enable therapeutic peptides to become a widely accepted drug class.

Conclusions:

• Technological innovations are effectively addressing the challenges of protease sensitivity and short half-life in therapeutic peptides.
• The integration of advanced selection and engineering methods is crucial for peptide drug viability.
• Therapeutic peptides are increasingly likely to achieve broad clinical acceptance and market presence.